key: cord-0734219-jjzd3jxw authors: Bagacean, Cristina; Letestu, Rémi; Al-Nawakil, Chadi; Brichler, Ségolène; Lévy, Vincent; Sritharan, Nanthara; Delmer, Alain; Dartigeas, Caroline; Leblond, Véronique; Roos-Weil, Damien; Tomowiak, Cécile; Merabet, Fatiha; Béné, Marie C; Clavert, Aline; Chaoui, Driss; Genet, Philippe; Guieze, Romain; Laribi, Kamel; Drénou, Bernard; Willems, Lise; Puppinck, Christian; Legendre, Hugo; Troussard, Xavier; Malartre, Stéphanie; Cymbalista, Florence; Michallet, Anne-Sophie title: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 inpatients with chronic lymphocytic leukemia date: 2021-12-01 journal: Blood Adv DOI: 10.1182/bloodadvances.2021006215 sha: 354b2192c5f8424c6c3a553d10a66972accef0eb doc_id: 734219 cord_uid: jjzd3jxw Immunocompromised individuals such as chronic lymphocytic leukemia (CLL) patients are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate SARS-CoV-2-specific antibody responses in CLL patients, after the first, second and third doses of the BNT162b2 and mRNA-1273, and after a single dose for patients with confirmed prior COVID-19. Five hundred and thirty patients were included in the study. Patients received 2 doses at a 4-week interval, and a third dose if seronegative after thesecond dose. Response rate was 27% post-dose 1 and 52% post-dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patientspreviously treated by chemoimmunotherapy (60%). Among patients on therapy, patients on BTKi alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients on venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariate analysis identified as independent predictors of the absence of seroconversion: age >65 years, ongoing CLL treatment and gamma-globulins ≤6g/L. Post-dose 2 seronegative patients had a global post-dose 3 response rate of 35%. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies. Immunocompromised individuals such as chronic lymphocytic leukemia (CLL) patients are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate SARS-CoV-2-specific antibody responses in CLL patients, after the first, second and third doses of the BNT162b2 and mRNA-1273, and after a single dose for patients with confirmed prior COVID-19. Five hundred and thirty patients were included in the study. Patients received 2 doses at a 4-week interval, and a third dose if seronegative after the second dose. Response rate was 27% post-dose 1 and 52% post-dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patients previously treated by chemoimmunotherapy (60%). Among patients on therapy, patients on BTKi alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients on venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariate analysis identified as independent predictors of the absence of seroconversion: age >65 years, ongoing CLL treatment and gamma-globulins ≤6g/L. Post-dose 2 seronegative patients had a global post-dose 3 response rate of 35%. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is responsible for an ongoing pandemic. Although Phase III mRNA vaccine trials demonstrated excellent efficacies, a number of subpopulations including immunocompromised individuals were excluded from these trials. 1, 2 Chronic lymphocytic leukemia (CLL) is associated with immune dysregulation, due to hypogammaglobulinemia, impaired cellular immunity and therapy-related immunosuppression. Impaired immune responses to vaccination have been previously reported in CLL, notably with attenuated vaccine-induced immunity in patients heavily treated or undergoing treatment with Bruton tyrosine kinase inhibitors (BTKi). [3] [4] [5] Furthermore, in a recent Israeli study, a suboptimal response was reported after 2 doses of COVID-19 mRNA vaccine. 6 In view of our preliminary results, the French National Authority for Health recently recommended the use of a third dose of vaccine in CLL patients. The objective of our study was the evaluation of SARS-CoV-2-specific antibody responses after the first, second and third doses of the BNT162b2 and mRNA-1273 vaccines, and after a single dose for patients with confirmed prior COVID-19. Data were collected retrospectively from 17 FILO centers and the French CLL patients' association (SILLC). The study was approved by the Health Data Hub. All patients From March to July 2021, a total of 530 patients was included in this study ( were all seronegative after the second dose of vaccine. This difference was not reported in the Israeli cohort, as patients receiving venetoclax monotherapy were not segregated from those receiving venetoclax+anti-CD20 mAb ( Figure 1B) . 6 The negative impact of BTKi or anti-CD20 mAbs on antibody production is not surprising and is in line with other vaccination efficacy reports. 4, 5, 8 In We analyzed the post-dose 2 antibody titers tested with the Abbott SARS-CoV-2-IgG II Quant anti-Spike assay of patients for whom post-dose 3 response was available (n=39). Patients who had weak post-dose 2 responses, although below the threshold titer (6.8